Date: August 26, 2015  Administrative Circular: 2015:14

ATTN: Medical Health Officers and Branch Offices
     Public Health Nursing Administrators and Assistant Administrators
     Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual,
Chapter 2 - Immunization Program, Section VII – Biological Products

Section VII – Biological Products

Hepatitis B Vaccine Pre-Exposure (Recombivax HB®)
Revision date and page number corrected on page header. Content unchanged.
- The revision date and page number for the Hepatitis B Pre-exposure page (containing the footnotes) was inadvertently changed online when Section VII was updated in June of this year. To avoid confusion in future updates, we have provided the correct Hepatitis B Pre-exposure page numbered 18 and dated June 2014. Those with the page numbered 18a should remove it and replace it with the page numbered 18.

Please remove page number: 18a dated January 2012
Please add new page number: 18 dated June 2014

Human Papillomavirus Vaccine (Gardasil®)
New indications added related to the expanded eligibility for select male populations.

Footnotes revised to remove information related to grade 9 students, and to clarify minimum intervals.

Special considerations updated and wording revised to be gender neutral.

Please remove page numbers: 24a & 24b dated October 2014
Please add new page numbers: 24a & 24b dated August 2015
Human Papillomavirus Vaccine (Cervarix®)
Indications updated.

2-dose series for girls 9-14 years (inclusive) added, as per NACI. A footnote was added indicating that Gardasil is the product recommended and provided for this age cohort.

Footnote added indicating minimum intervals.

Please remove page numbers: 25a & 25b dated June 2015 & July 2013
Please add new page numbers: 25a & 25b dated August 2015

Trivalent Inactivated Influenza Vaccine (Inactivated Subunit, Adjuvanted) (FLUAD®)
Revision date corrected on page header. Content unchanged.

Please remove page number: 34 dated July 2014
Please add new page number: 34 dated August 2015

Meningococcal C Conjugate (MCC) Vaccine
Meningitec® information removed as this vaccine is no longer supplied in Canada.

Indications and special considerations updated indicating that Menjugate® is the product to be used for grade 6 students for the 2015-2016 school year.

Administration information for Menjugate® updated.

Please remove page numbers: 39 & 40 dated September 2014 & June 2015
Please add new page numbers: 39 & 40 dated August 2015

Meningococcal Quadrivalent Conjugate Vaccines (Groups A, C, Y, W-135)
Special consideration added related to high risk children up to 10 years of age who have only received one dose of meningococcal quadrivalent conjugate vaccine.

Please remove page numbers: 41 & 42 dated February 2015
Please add new page numbers: 41 & 42 dated August 2015
If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC at telephone (604) 707-2555, fax (604) 707-2515 or by email at Christine.halpert@bccdc.ca.

Sincerely,

Monika Naus, MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:
Dr. Perry Kendall
Provincial Health Officer
Dr. Bonnie Henry
Deputy Provincial Health Officer
Craig Thompson
Director of Immunization
Healthy Populations and Development Branch
Warren O'Briain
Executive Director
Healthy Populations and Development Branch